14 January 2016
IntegraGen Reports 2015 Revenue
IntegraGen reports its 2015 Revenues : Strong cash position; Robust development of activity on genomic platforms; Lower revenue for genomic services business.
02 December 2015
IntegraGen Collaborating with FIRE-3 Clinical Trial Investigators to Study hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker
IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.
17 November 2015
Gustave Roussy and IntegraGen announce completion of 1,000 analyses with clinical research sequencing platform
Gustave Roussy and IntegraGen announced the achievement of one thousand genomic analyses utilizing their combined sequencing platform. The molecular profiles of cancer patients were analyzed as part of personalized medicine clinical trials being conducted at Gustave Roussy. The ability to deliver these results in less than three weeks (…) »
02 October 2015
IntegraGen Announces H1 2015 Financial Results
IntegraGen today announced its financial results for the 1st half of 2015 ending on 30 June 2015.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on 1 October, 2015.
25 August 2015
Results from sequencing of 193 liver tumors performed by IntegraGen identifies potential role of a new virus in the development of liver cancer
IntegraGen announces a publication in Nature Genetics reporting the role of adeno-associated virus type 2 (AAV2) virus in the development of liver cancer. Professor Jessica Zucman-Rossi and her colleagues at Inserm Unit 1162 in Paris, supported by expert sequencing services from IntegraGen, identified the role of AAV2, a (…) »
10 July 2015
IntegraGen Reports Revenue for First Half of 2015
IntegraGen today announced its sales for the first half 2015. Sales for IntegraGen’s business totaled € 2.6 million as of June 30, 2015, up 1% compared to the first half of 2014. The company also reported that it experienced a substantial growth in new projects during the first half of 2015 increasing by (…) »
08 July 2015
AP-HP : Georges Pompidou European Hospital and IntegraGen announce a cooperation agreement for access to a high-throughput sequencing platform
IntegraGen and the Georges Pompidou European Hospital (HEGP) announce the signing of an agreement to develop the use of high-throughput sequencing techniques to improve the care of patients.
01 June 2015
IntegraGen presents positive data from two new studies on miR-31-3p biomarker at ASCO 2015
Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with (…) »
16 April 2015
IntegraGen presents data on mir-31-3p biomarker during 2015 European Lung Cancer Conference
Results from a study exploring the role of the microRNA biomarker miR-31-3p in patients with advanced adenocarinoma of the lung were presented during the 2015 European Lung Cancer Conference (ELCC) held in Geneva, Switzerland. The data presented demonstrated that the expression of miR-31-3p is associated with the histological type of the (…) »
10 April 2015
IntegraGen announces 2014 financial results
IntegraGen today announced its financial results for the year ended 31 December 2014.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on April 9, 2015.